Comparative Pharmacology
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus PMB 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus PMB 400.
NORGESTIMATE AND ETHINYL ESTRADIOL vs PMB 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via estrogen receptor; norgestimate is a progestin that inhibits ovulation and thickens cervical mucus.
PMB 400 is a combination of progesterone and micronized estradiol; progesterone suppresses gonadotropin secretion and transforms proliferative endometrium into secretory endometrium, while estradiol replaces endogenous estrogen production and promotes growth of reproductive tissues.
One tablet (norgestimate 0.250 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days followed by 7 placebo tablets.
1 tablet (400 mg Pregabalin, 400 mg Mirogabalin, 100 mg Benfotiamine) orally once daily.
None Documented
None Documented
Norgestimate: ~21.3 hours (range 16-36 hours); active metabolite 17-deacetyl norgestimate: ~33.2 hours (range 22-45 hours). Ethinyl estradiol: ~17.1 hours (range 14-22 hours). Terminal half-life supports once-daily dosing; steady-state achieved within 10-14 days.
Terminal elimination half-life is 12-16 hours in adults with normal renal function; may be prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Urine (primarily as glucuronide and sulfate conjugates; ~50-60% of dose), feces (~30-40% of dose as metabolites), minimal unchanged drug in urine
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; hepatic metabolism via CYP3A4 produces inactive metabolites, with biliary/fecal excretion of metabolites (20-30%) and parent compound (<5%).
Category D/X
Category C
Estrogen
Estrogen/Progestin Combination